News | Artificial Heart | March 24, 2016

New Documentary Traces History of SynCardia Total Artificial Heart

Produced by Retro Report for The New York Times, film traces the modern-day SynCardia Heart full circle from its origins as a permanent heart to successfully pioneering use as a bridge to transplant to a new FDA clinical study for permanent use

SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times

March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and modern use of the SynCardia temporary Total Artificial Heart (TAH-t). The 12-minute film, “A Change of Heart,” re-examines this leading story of the past and brings viewers through to today’s news.

This documentary details the development of the SynCardia Total Artificial Heart and its direct predecessor, the Jarvik 7. Like a heart transplant, the TAH-t is the only approved device that eliminates end-stage biventricular (both sides) heart failure. This fatal condition results when the native heart's two ventricles can no longer pump enough blood for a patient to survive.

Through personal stories of surgeons and SynCardia Total Artificial Heart patients, this documentary takes the audience from the first use of a Total Artificial Heart for permanent use in 1982 to today's use as a bridge to a donor heart transplant.

"Use of SynCardia's Total Artificial Heart Technology has gone full circle," said Michael P. Garippa, SynCardia's CEO and president. "The first implants were for permanent use. For the last 30 years the TAH-t has been used as a bridge to transplant. Now we are in an FDA [U.S. Food and Drug Administration] Investigational Device Exemption (IDE) clinical study for 19 destination therapy patients who do not qualify for a donor heart transplant."

"This study is generating data on the effective use of the SynCardia Heart as a way for patients to recover from heart failure and continue with a near-normal lifestyle without a human heart," Garippa said.

The 70cc SynCardia Total Artificial Heart, when used for destination therapy, is an investigational device, limited by United States law to investigational use.

For more information: www.syncardia.com

Related Content

News | Artificial Heart

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

Home June 23, 2021
Home
News | Artificial Heart

February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval ...

Home February 10, 2021
Home
News | Artificial Heart

May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first ...

Home May 27, 2020
Home
News | Artificial Heart

March 10, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total ...

Home March 10, 2020
Home
News | Artificial Heart

December 11, 2017 — CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science ...

Home December 11, 2017
Home
News | Artificial Heart

October 27, 2017 — CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its ...

Home October 27, 2017
Home
News | Artificial Heart

October 26, 2016 — The U.S. Food and Drug Administration (FDA) provided an update and additional information regarding ...

Home October 26, 2016
Home
News | Artificial Heart

August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge ...

Home September 13, 2016
Home
News | Artificial Heart

September 9, 2016 — Carmat announced that the first implantation of its bioprosthetic artificial heart within the ...

Home September 09, 2016
Home
News | Artificial Heart

March 18, 2016 — A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant ...

Home March 18, 2016
Home
Subscribe Now